再発膠芽腫に対する改良型ポリオウイルス・ワクチン【NEJM】

N Engl J Med 2018年6月26日オンライン版

Recurrent Glioblastoma Treated with Recombinant Poliovirus

The prognosis of patients with recurrent World Health Organization (WHO) grade IV malignant glioma is dismal, and there is currently no effective therapy. We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio–rhinovirus chimera (PVSRIPO). PVSRIPO recognizes the poliovirus receptor CD155, which is widely expressed in neoplastic cells of solid tumors and in major components of the tumor microenvironment.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*